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Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) has traditionally been defined as pulmonary hypertension (PH) caused by single or recurrent pulmonary emboli arising from deep vein thrombosis (DVT). These embolic events are not always clinically apparent. In such cases, a silent acute pulmonary embolism (PE) is the initiating event, and subsequent pulmonary vascular remodeling (small vessel disease) causes progression to PH. Hence, modern therapies for pulmonary arterial hypertension (PAH) may be efficacious in patients with CTEPH [1, 2] . Accurate diagnosis of CTEPH is very important because certain procedures have been shown to improve outcome. For example, CTEPH can be cured by pulmonary endarterectomy (PEA) [3] [4] [5] [6] [7] [8] [9] , and balloon pulmonary angioplasty (BPA) may improve pulmonary hemodynamics and survival in patients with distal-type disease [10] [11] [12] [13] .
Here, we review recent progress in the diagnosis and management of CTEPH.
Definition
CTEPH develops because of chronic occlusion of pulmonary arteries by organized thrombi. It is defined as a mean pulmonary arterial pressure (Ppa)≥25 mmHg and normal pulmonary capillary wedge pressure despite anticoagulation therapy for more than 3 months [14, 15] . In patients who meet these criteria and have segmental defects on perfusion scans, the diagnosis of CTEPH should be confirmed by chronic embolic findings on pulmonary angiography or computed tomographic (CT) pulmonary angiography.
Epidemiology
In the United States, it is estimated that an acute PE occurs in 0.5 to 0.6 million individuals each year, and CTEPH develops in approximately 0.1% to 0.5% of patients surviving the acute phase of PE [3, 16] . However, the incidence of CTEPH may be higher; a recent study showed that CTEPH occurs in 3.8% of patients with a history of acute PE [17] . Another study revealed that the cumulative incidence of CTEPH is 0.57% in all patients with PE and 1.5% in patients with unprovoked PE [18] . Thus, physicians should be aware of the risk of progression to CTEPH when treating patients with acute PE. In Japan, the Respiratory Failure Research Group from the Ministry of Health, Labor and Welfare (MHLW) established criteria for the diagnosis of CTEPH during a nationwide survey in 1997. The number of patients with CTEPH was estimated to be 450 (95% confidence interval, 360-530) [19] , which designated it as a specified rare and intractable disease. The MHLW has since conducted annual epidemiological surveys of CTEPH. In 2010, 1288 patients with CTEPH were registered as having this specified rare and intractable disease [20] .
Etiology and characteristics of Japanese CTEPH
The pathogenic mechanisms that cause CTEPH are still uncertain. CTEPH is considered as a chronic condition occurring in patients with a history of acute PE caused by DVT. However, up to 40% of patients with CTEPH have not had clinically apparent acute embolic episodes [21] .
CTEPH results from obstruction of more than 40% of the pulmonary vascular bed by unresolved thromboemboli [22] . Thrombophilia due to mutations in protein C, protein S, antithrombin, prothrombin, or factor V has not been significantly associated with CTEPH. Factors that have been linked to CTEPH include anti-cardiolipin antibodies, which are found in 10% to 20% of patients, and elevated factor VIII [23, 24] . Several additional risk factors have been associated with CTEPH, including chronic inflammatory disorders, myeloproliferative syndromes, and splenectomy [25] . The association of CTEPH with these conditions suggests that chronic inflammatory processes are involved in its pathogenesis.
Patients with CTEPH may remain asymptomatic for months or years ("honeymoon period") regardless of whether or not they have a history of acute embolic episodes. The pathological mechanisms that occur during this asymptomatic period are unknown. It is possible that recurrent thromboembolism and in situ thrombosis are involved in the progression to symptomatic PH. However, several investigators have suggested that PH results from pulmonary vascular remodeling (small vessel disease) that occur secondary to the initial PE event. If CTEPH is indeed a small vessel disease, it may develop in a manner similar to PAH [1, 2, 26] .
Analysis of a subset of 519 patients among the 1288 patients in the MHLW CTEPH registry in 2011 revealed that female patients outnumbered male patients (2.6:1), and the mean age was 64713 years. Interestingly, while no gender difference was observed in younger patients, the female-to-male ratio increased in patients older than 40 years of age [27] .
A comparison of important clinical characteristics between patients in the Japanese MHLW registry and those in the international registry is shown in Table 1 [28] . Japanese patients were predominantly female, had better World Health Organization (WHO) functional status, mild hemodynamic impairment, fewer incidents of acute PE, and fewer coagulopathies. Significantly fewer patients in the Japanese registry underwent PEA, which may be related to the fact that patients who improved after surgery were excluded from the registry until 2009. Nonetheless, fewer patients in the Japanese registry underwent surgical treatment. Similar to patients in the international registry, however, half of the Japanese patients underwent operations at Chiba University Hospital, one of the PEA referral centers in Japan [29] . Japanese patients were more likely to have an inferior vena cava filter, even in medically treated cases. In addition, Japanese patients were more likely to be prescribed modern PAH therapies, even in surgically treated cases [27] .
Shigeta et al. reported a Japanese series in which female patients with CTEPH were more likely to be elderly, have fewer occurrences of DVT or acute embolic episodes, and have different clinical characteristics than male patients with CTEPH [30] .
Tanabe et al. found a significantly higher frequency of HLA-Bn5201 in Japanese patients with CTEPH (40%) than in normal controls (24%) or in patients with acute PE (10%), and HLA-Bn5201-positive patients were predominantly female (83%) [24] . The frequency of HLA-Bn5201 in patients with CTEPH was similar to that reported in patients with Takayasu arteritis (41.3%), a chronic vasculitis involving the aorta and its major branches as well as the coronary and pulmonary arteries. Multicenter Japanese studies have revealed a strong association of IKBL n p03 (odds ratio, 2.33; 95% confidence interval, 1.49-3.66; p ¼0.00017; pc¼ 0.033) and Bn5201 (odds ratio, 2.47; 95% CI, 1.56-3.90; p¼ 0.000086; pc¼ 0.016) with DVTnegative CTEPH [31] . IKBL n p03 is a polymorphism in the promoter region of the gene coding for nuclear factor κB inhibitor-like protein (IKBL-p allele), and it has been associated with Takayasu arteritis [32] . Hence, inflammatory processes may be involved in the pathogenesis of DVTnegative CTEPH in Japanese populations. It should be noted that Takayasu arteritis was differentiated from CTEPH in this study by CT angiography and by the absence of macroscopic findings during surgery. We have observed thrombus growth into the proximal side of the pulmonary artery in 3 HLA-Bn5201-positive patients whose C-reactive protein levels were o0.3 mg/dL. The results of one autopsy showed diffuse inflammatory cell infiltrates in the media of the large elastic pulmonary arteries to which thrombi were attached. Those findings mimicked Takayasu arteritis but were differentiated from this entity based on the lack of adventitial lesions. It is possible that more cases of undiagnosed pulmonary arteritis secondary to thrombi have occurred in HLA-Bn5201-positive patients with CTEPH [24] .
Clinical presentations
Progressive exertional dyspnea and exercise intolerance are common in patients with CTEPH, whether or not they have a history of clinically relevant acute PE. A "honeymoon period" between the acute episode and the diagnosis of CTEPH is common and may last from months to years [2, 16, 22] . In patients who do not have a known history of acute PE, progressive exertional dyspnea and fatigue appear to be caused by elevated Ppa and decreased maximal cardiac output, similar to patients with PAH. As the disease progresses, patients develop exertional chest pain, syncope, and lower extremity edema, which are indicative of decreased cardiac output at rest and right heart failure. In a study of patients with inoperable CTEPH, patients with a mean Ppa440 mmHg had a poor prognosis (5-year survival,~30%) but those with a mean Ppao30 mmHg did not [33] . Hence, precise evaluation and surgical intervention, when appropriate, are essential to survival.
Physical findings of CTEPH are often subtle but may include a prominent pulmonary component of S2 and a systolic murmur reflecting tricuspid regurgitation. Signs of right heart failure (distended neck veins, edema, ascites, and acrocyanosis) occur later in the course of the disease. Approximately 30% of patients have a bruit somewhere in the lung fields. These flow murmurs originate from turbulent blood flow through partially occluded vessels or through recanalized thrombi [2] .
4.2.
Diagnostic strategy PH, including CTEPH, should be suspected in all patients with unexplained dyspnea [14, 15] . Suspicion should be even higher in patients who have had a PE and/or DVT. The first objective finding in early CTEPH may be desaturation during exercise [3] . Echocardiography is widely used as an initial test for detecting PH and excluding left heart disease and shunt.
Screening echocardiography, performed 6 weeks after the diagnosis of acute PE, can identify patients with persistent PH and may be of value in planning follow-up care [34] . Chest roentgenography may be normal in early CTEPH and is thus not diagnostic, although several abnormalities may occur in later stages of disease [3] . Electrocardiography is also nondiagnostic; however, certain findings are associated with PH, including right ventricular hypertrophy or strain with right axis deviation, complete or incomplete right bundle branch block, and nonspecific ST-T changes in leads V1 to V3. PaO 2 may also be normal, although the alveolar-arterial oxygen tension gradient is typically widened. Ventilation/perfusion (V/Q) scans are excellent noninvasive tests with which to distinguish CTEPH from PAH [14, 15] , while CT angiography is useful for differentiating CTEPH from arteritis, tumors, and congenital anomalies of the pulmonary arteries [15, 21, 35] . Pulmonary angiography is still considered the gold standard for evaluation of CTEPH. Right heart catheterization is required to confirm precapillary PH (mean Ppa≥25 mmHg and pulmonary capillary wedge pressure ≤15 mmHg) after patients have been adequately anticoagulated for more than 3 months [14, 15] .
Imaging

Chest roentgenography
In patients with CTEPH, chest roentgenography may appear normal and demonstrate clear lung fields, but close examination may reveal areas of hyperperfusion or hypoperfusion with enlargement or asymmetry of the central pulmonary arteries. Right atrial and right ventricular enlargement may occur in PH and will appear on lateral CT views as obliteration of the retrosternal space by the cardiac shadow [3] . Satoh et al. reported that an avascular area or marked dilatation of the right descending pulmonary artery, together with pleuritic changes, suggests the presence of CTEPH [36] .
V/Q scans and single photon emission computed tomography
In patients with unexplained PH, a V/Q scan is recommended to exclude CTEPH [2, 21, 22, 25] . The presence of either normal or mottled perfusion scans can suggest PAH, while even one unmatched perfusion defect suggests CTEPH ( Fig. 1 ). Matched perfusion defects and elevated ventilation-to-perfusion defects suggest PH due to lung disease and/or hypoxemia. In a study of 227 patients that compared detection of CTEPH by V/Q scan with detection by multi-slice computed tomographic pulmonary angiography (CTPA), V/Q scans demonstrated a sensitivity of 96%-97.4% and a specificity of 90%-95% and CTPA demonstrated a sensitivity of 51% and a specificity of 99% [37] . Although V/Q scans demonstrated a higher sensitivity in detection of CTEPH ( Fig. 1 ), V/Q findings have been shown to understate the severity of angiographic findings and do not correlate with pulmonary vascular resistance (PVR) or mean Ppa [38] .
A recent pilot study comparing single-photon emission computed tomography (SPECT) perfusion scans with CTPA showed that SPECT is more sensitive than CTPA in identifying obstructed segments [39] ( Fig. 2a and b ). The investigators suggest that this increased sensitivity might be important not only during initial evaluations but also during postsurgical follow-up care [39] .
CTPA
CTPA is often the first choice for imaging in patients who have had a recent acute embolic episode. CT angiography is also indicated when a V/Q scan is indeterminate or shows perfusion defects. Recently, 64-or 320-detector row CTPA has been shown to be an accurate and reliable noninvasive alternative to pulmonary angiography in evaluating patients with CTEPH. The sensitivity and specificity of CTPA in detecting thromboembolic findings were 97.0%-98.3% and 94.8%-97.1% at the main/ lobar level, respectively, and 85.8%-94.1% and 92.9%-94.6% at the segmental level, respectively [40, 41] . Three-dimensional CT angiography reveals chronic embolic findings consistent with those in pulmonary angiography ( Fig. 3) ; however, poor correlation between the CT-derived obstruction index and PVR has been reported [42] . Pulmonary vascular remodeling may result in a disproportionately elevated PVR compared with that produced by proximal thrombi. Recently, the development of electrocardiography-gated CTPA has allowed for the simultaneous evaluation of thrombi location and right ventricular function. Sugiura et al. reported good correlation between bowing of the interventricular septum (expressed as curvature) and systolic Ppa (r¼ −0.79, po0.001) and mean Ppa (r¼−0.86, po0.001) [41] (Fig. 4 ). Liu et al. reported that the Cobb angle (the angle between the interventricular septum and the line between the sternal midpoint and thoracic vertebral spinous process, measured during diastole) on transverse images is a reliable tool for estimating PVR [42] . CTPA is also used to differentiate CTEPH from other pulmonary vascular diseases in patients with perfusion defects. Unilateral obstruction on perfusion scans is rare in CTEPH but suggests the presence of other diseases, such as sarcoma of the pulmonary artery ( Fig. 5c ), Takayasu arteritis ( Fig. 5d) , cancer, or mediastinal fibrosis [15, 21, 35] . In addition, 3-dimensional CTPA is used to differentiate CTEPH from congenital anomalies of the pulmonary arteries [43] . Highresolution CT of the lung shows a diagnostic pattern of mosaic attenuation (mixed hypoperfused and hyperperfused areas) in CTEPH, independent of the presence of contrast media (Fig. 2d) [35] .
Dual-energy CTPA allows for evaluation of lung perfusion and thrombus location. Simultaneous acquisition of data sets at 80 and 140 kV can be used to visualize iodine distribution maps (lung perfusion blood volume images) in the pulmonary parenchyma, which reflect lung perfusion. Imaging of lung perfusion blood volume by dual-energy CT has been reported to be comparable to SPECT perfusion scans in establishing a diagnosis of CTEPH [44] .
Magnetic resonance imaging
Magnetic resonance (MR) imaging may also provide a clear diagnosis of CTEPH [33] , but a recent report suggested that it is less effective than multidetector CTPA in assessing the pulmonary arteries of patients with CTEPH [45] . However, contrast-enhanced MR angiography may be useful in discriminating central thromboembolic lesions from tumors; with contrast-enhanced MR, the latter are enhanced with gadolinium, whereas the former are not [2] . Moreover, MR imaging is the gold standard for quantifying right ventricular function and dimensions in patients with PAH or CTEPH [35] . This is important because Reesink et al. reported that after PEA, changes in total PVR correlate with changes in right ventricular ejection fraction, right ventricular mass, and leftward ventricular septal bowing [46] .
Pulmonary angiography
Pulmonary angiography is the gold standard for diagnosing CTEPH and assessing operability [14, 15, 21] . Five distinct angiographic findings correlate with the presence of organized thromboemboli: pouch defects, webs or bands, intimal irregularities, abrupt narrowing, and complete obstruction [47] . Pulmonary angiography allows for visualization of proximal and distal thromboembolic findings in the elastic pulmonary arteries. It also helps to determine if thromboemboli are surgically accessible by providing an assessment of capillary perfusion (Fig. 6 ) [48] . Pulmonary angiography can be performed safely in patients with severe CTEPH and is often performed in conjunction with a diagnostic right heart catheterization [49] . Selective nonionic contrast injections into the right and left main pulmonary arteries should be performed on a biplane digital subtraction system. It should be noted that, unlike CTPA, pulmonary angiography cannot fully assess the pulmonary trunk [45] .
Classic therapy
Patients with CTEPH, whether treated medically or with PEA, must receive lifelong anticoagulant therapy to avoid a recurrence of venous thromboembolism and to prevent progression of thrombus growth within the pulmonary arteries [14, 15, 21] . Warfarin is the most commonly used anticoagulant and is generally administered to achieve a prothrombin time/international normalized ratio of 2 to 3 (1.5 to 2.5 according to Japanese guidelines) [14, 15] . Patients who experienced an acute embolic episode show rapid disease progression. When D-dimer levels are high during disease progression, thrombolytic therapy may improve outcome [15] . Finally, although there is no conclusive evidence regarding the utility of oxygen therapy in patients with CTEPH, it is believed to improve both quality of life and prognosis [15] .
PEA
PEA, a standard surgical procedure for removal of surgically accessible central thrombi, is performed worldwide, usually at expert centers [3] [4] [5] [6] [7] [8] [9] . PEA offers early and significant decreases in both mean Ppa and PVR and later improvements in gas exchange [50] .
7.1.
Indication for surgery
The selection criteria for PEA include (1) mean Ppa430 mmHg (resulting in a calculated PVR of 4300 dyn s cm −5 ) even after oral anticoagulant therapy for 46 months, (2) WHO functional class ≥2, (3) thrombi that are accessible to current surgical techniques (i.e., located in the main, lobar, or segmental arteries), and (4) absence of severe associated disease [15, 51] . In symptomatic young patients who want to improve their daily activity, surgery should be considered even in those with mild resting PH and exercise-induced PH [3, 26] .
Surgical technique
The PEA procedure developed at the University of California, San Diego is performed through a median sternotomy and requires intermittent deep hypothermic circulatory arrest [3, 51] . This surgical procedure has been described in detail elsewhere [3, 51] . Briefly, PEA is performed with intermittent circulatory arrest to avoid bleeding from systemic-to-pulmonary collateral circulation, and deep hypothermia (20 1C) is induced to prevent brain damage. It is important to find the correct dissecting plane during endarterectomy, because the plane is followed all the way to the lobar, segmental, or subsegmental arteries of each lobe.
An inferior vena cava filter should be considered before surgery to prevent recurrent emboli within the perioperative period, particularly in patients with a history of DVT [3, 26, 51] . Cardiovascular risk should be assessed preoperatively by coronary angiography or CT coronary angiography, and coronary artery bypass surgery, if necessary, can be performed without risk [38, 48] .
Short-term results
Thistlethwaite et al. reported an overall mortality of 4.7% in 1100 consecutive patients who underwent PEA [51] . Patients with a postoperative PVR 4500 dyn s cm −5 had significantly higher mortality (5.7%) compared with those with a postoperative PVR o500 dyn s cm −5 (1.2%). The investigators classified intraoperative thromboembolic disease into 4 types: type 1, fresh thrombus in the main/lobar pulmonary arteries (37.7%) (Fig. 6b) 
Long-term results
The University of California, San Diego group achieved a 6-year survival rate of 75% in 308 patients who underwent PEA between 1970 and 1994 [4] . 
Risk factors for surgery
Several reports have demonstrated that high preoperative PVR is a significant prognostic factor for postsurgical complications [1, 2, 6, 21] . One international registry showed that the mortality rate was 2.8% in patients with PVRs between 400 and 800 dyn s cm −5 , 5.8% in patients with PVRs between 800 and 1200 dyn s cm −5 , and 10.6% in patients with PVRs 41200 dyn s cm −5 [6] . One explanation for this is that patients with PVRs that are disproportionate to the amount of visible central lesion obstruction are likely to have distal thrombi and severe pulmonary vascular remodeling, which results in poor outcome after PEA [1, 2] . Kim et al. used pulmonary arterial occlusion waveform analysis to determine that upstream resistance was inversely correlated to both postoperative total pulmonary vascular index and mean Ppa. Further, all non-survivors had upstream resistance o60%, indicating peripheral-type disease [52] . Tanabe et al. recently used the capillary phase in pulmonary angiography to focus on subpleural perfusion and found that the absence of subpleural perfusion in any segment, coupled with high PVR, might be related to small vessel disease and results in poor outcome after surgery [48] . 8.
Modern PAH therapy
The progression of CTEPH may be caused by small vessel disease, similar to PAH, but no medications for PAH have been approved for the treatment of CTEPH [1, 2] . However, medications for PAH been used off-label in patients with CTEPH who have inoperable disease or patients with persistent PH after PEA and have been used as therapeutic bridges before PEA [26] . According to the international registry, more than one-third of patients with CTEPH were treated medically. Of those, half received modern PAH therapies such as phophodiesterase-5 inhibitors and endothelin receptor antagonists [28] . Similarly, a Japanese series showed that more than half of patients with CTEPH were treated with the modern PAH medications beraprost, bosentan, or sildenafil [27] .
Endothelin receptor antagonists
In a randomized controlled trial (RCT) of patients with inoperable disease or persistent PH after surgery, treatment with bosentan led to a significant improvement in PVR (−24.1% of baseline) but did not significantly improve 6-min walk distance (6MD) [53] . In a recent meta-analysis of 11 studies (totaling 269 patients), bosentan was associated with improved pulmonary hemodynamics and exercise capacity [54] . In an uncontrolled study of several types of PH, ambrisentan led to a modest increase in 6MD (mean, 17 m) in patients with CTEPH [55] .
Phosphodiesterase-5 inhibitors
Reichenberger et al. showed that sildenafil improved PVR and 6MD in an open-label study of 104 patients with inoperable CTEPH [56] . In a small double-blind RCT of patients with inoperable CTEPH, Suntharalingam et al. reported that sildenafil did not significantly improve 6MD relative to placebo but significantly improved several secondary endpoints at both 3 months (PVR and WHO class) and 12 months (6MD, PVR, WHO class) [57] . They further reported that the change in PVR after 12 months of treatment with sildenafil correlated with the change in PVR during vasoreactivity testing with sildenafil.
Prostanoids
Olchewski et al. reported the results of a RCT in which inhaled iloprost was tested in 203 patients with PH, including 57 patients with CTEPH. Iloprost improved exercise capacity and pulmonary hemodynamics compared with placebo, but the beneficial effect was less prominent in patients with CTEPH than in patients with PAH [58] . In an uncontrolled study of 28 patients with inoperable CTEPH, subcutaneous treprostinil therapy significantly improved PVR. Furthermore, 5-year survival in patients treated with treprostinil was significantly better than in a historical control group (53% vs. 16%) [59] . In a retrospective study of 27 patients with inoperable CTEPH, epoprostenol improved mean Ppa, total PVR, 6MD, and New York Heart Association class [60] . In an uncontrolled study in Japan, Ono et al. reported that oral beraprost improved New York Heart Association class in 10 Recently, Japanese investigators improved upon the traditional BPA technique by using smaller-sized balloons and dilating fewer lobes per procedure under the application of modern PAH therapies and noninvasive positive pressure ventilation. These modifications resulted in improved efficacy and fewer severe complications due to reperfusion injury [11] [12] [13] (Fig. 7) . Of note, it is possible to perform BPA multiple times in patients who have unresolved PH after PEA. Although the long-term survival benefit of BPA remains uncertain, improved hemodynamics could result in improved survival. It remains unclear, however, if BPA improves gas exchange, and the necessity of modern PAH therapy before and/or after BPA remains controversial.
Current practical treatment
Recent surgical techniques have decreased the mortality rate during PEA and made it possible to perform endarterectomy in patients with distal-type thrombi (type 3). However, modern PAH therapy and BPA are emerging as alternative treatments for patients with surgically inaccessible disease and in patients who refuse PEA. BPA could be a high-risk procedure in patients with high PVR (which indicates severe pulmonary vascular remodeling), in contrast to patients with mild to moderate PVR (which indicates distal thrombi). However, BPA in combination with modern PAH therapy might be safe and practical in severe cases. We suggest that a specialized medical team, including at least one expert surgeon, should make decisions regarding the patient's candidacy for PEA and/or BPA.
Future treatment
Maruoka et al. and Sakao et al. reported that organized thrombotic tissue in CTEPH is composed of myofibroblastlike cells, characterized as hyperproliferative and anchorage independent. Myofibroblast-like cells promote endothelial cell transition to other mesenchymal phenotypes and/or induce endothelial cell dysfunction [67, 68] . Ogawa et al. reported that inhibition of mTOR attenuates reduced platelet-derived growth factor-stimulated cell proliferation in CTEPH [69] . Both groups propose that rapamycin may have therapeutic benefit in CTEPH [67, 69] . Imatinib and other antiproliferative therapies are being evaluated in PAH [70] , but the value of systemic or local antiproliferative therapy in patients with CTEPH requires further investigation.
Conclusion
Modern PAH therapies may have beneficial effects in CTEPH, and clinical studies investigating new drugs for patients with inoperable CTEPH are under way. Recent advances in BPA are likely to change the CTEPH treatment algorithm. It is important to diagnose CTEPH early to determine surgical candidacy and reduce surgical risk. To prevent the progression of CTEPH, the mechanisms underlying the chronicity of PE should be elucidated, as well as the role of endothelial dysfunction, inflammation, and hyperproliferative cells. Toshihiko Sugiura has no potential conflict of interests.
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